The risk of malabsorption of DOAC after bariatric surgery is a cause of concern for health professionals looking after patients who have undergone bariatric surgery. The extent to which bariatric surgery alters the pharmacokinetics and pharmacodynamics of DOAC is unknown.
We are carrying out this survey to explore how bariatric surgical units across the UK are restarting DOACs after bariatric surgery.
We would appreciate if you could complete this short survey which is anonymous and will only take few minutes.
Please click on the link below which will take you straight to the survey:
M. Chatzikonstantinou, RCSEng post CCT Bariatric Fellow
W. Mon, Consultant Bariatric Anaesthetist
R. Batterham, Consultant Bariatric Physician
M. Adamo, Consultant Bariatric Surgeon
UCLH Bariatric centre for weight management and metabolic surgery